Anemia
News
L-glutamine to prevent sickle cell complications featured in FDA podcast
Hear the FDA’s DISCO account of the role of L-glutamine’s recent approval for the acute complications of sickle cell disease.
Conference Coverage
Folic acid fortification prevents millions of cases of anemia
A strong public health rationale for mandatory food fortification.
News
FDA panel backs licensure for epoetin alfa biosimilar
How could a new epoetin alfa biosimilar change care and what are some concerns?
News
FDA advisory committee supports L-glutamine for SCD
L-glutamine powder got the nod from the majority of the FDA’s Oncologic Drugs Advisory Committee for treatment of sickle cell disease.
From the Journals
Oral iron of no benefit in heart failure with iron deficiency
High-dose oral iron therapy doesn’t improve exercise capacity in the estimated 50% of patients with symptomatic heart failure who also have iron...
Conference Coverage
PPIs triple heart failure hospitalization risk in atrial fib patients
PARIS – Atrial fib patients taking proton pump inhibitors, largely unnecessarily, have a far greater risk of hospitalization for an acute heart...
From the Journals
Eltrombopag improves frequency, speed, robustness of hematologic recovery
Adding eltrombopag to standard immunosuppressive therapy markedly improved the hematologic recovery in patients with severe aplastic anemia.
News
FDA: REMS no longer necessary for epoetin, darbepoetin
The REMS program was put in place to make sure that the benefits of erythropoiesis-stimulating agents outweighed the risks when prescribed.
From the Journals
In beta thalassemia major, liver stiffness declines with deferasirox
For patients with beta thalassemia major, long-term chelation with deferasirox led to significant improvements in liver stiffness.
From the Journals
Testosterone Trials’ cardiac, cognitive results disappoint
Testosterone treatment may have beneficial effects on unexplained anemia or bone density, but may increase coronary artery plaque and offer no...
Conference Coverage
Phase II trial: Drug reduces sickle cell ‘pain crises’
Of patients in the SUSTAIN trail on high-dose crizanlizumab, 36% had no ‘pain crisis’ attacks.